Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer
- Citation:
- J Clin Oncol vol 38 (35) 4184-4193
- Year:
- 2020
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Secondary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pmc-release
- Note:
- Methodological:
- No
- Biospecimen:
- Yes
- SDC:
- No
- Book Volume:
- 10
- Pharmas:
- GlaxoSmithKline
- Grants:
- U10CA180821, U10CA180882, U24CA196171, R01CA229409, UG1CA233160, UG1CA233180, UG1CA233290, UG1CA233329, UG1CA233333, UG1CA233373, P50-CA58223, U10CA180888, UG1CA233160 (SWOG)
- Corr. Author:
- Authors:
- Aranzazu Fernandez-Martinez Ian E. Krop David W. Hillman Mei-Yin Polley Joel S. Parker Lucas Huebner Katherine A. Hoadley Jonathan Shepherd Sara Tolaney N. Lynn Henry Chau Dang Lyndsay Harris Donald Berry Olwen Hahn Clifford Hudis Eric Winer Ann Partridge Charles M. Perou Lisa A. Carey
- Networks:
- LAPS-CT018, LAPS-IL057, LAPS-MA036, LAPS-NC007, LAPS-NY016, LAPS-UT003
- Study
- CALGB-40601
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords:
- ORIGINAL REPORTS, Breast Cancer